Skip to main content

Select Drug Profiles

FDA Approves New Injectable Drug to Treat Schizophrenia

David B. Nash, MD, MBA

Optimizing Rheumatoid Arthritis Therapy: Using Objective Measures of Disease Activity to Guide Treatment

Gary M. Owens, MD

Stakeholder Perspective

Closing Gaps in Health Plan Performance with Stakeholder Collaboration

by F. Randy Vogenberg, PhD, FASHP

Evaluating the Expected Costs and Budget Impact of Interventional Therapies for the Treatment of Chronic Venous Disease

Rashad Carlton, PharmD, MSPH, Rajiv Mallick, PhD, Chelsey Campbell, PharmD, MBA, Aditya Raju, MS, BPharm, Thomas O'Donnell, MD, Michael Eaddy, PharmD, PhD, Michael Eaddy, PharmD, PhD, Michael F. Murphy, MD, PhD

Stakeholder Perspective

A Teachable Moment in Health Benefits Design

by Michael F. Murphy, MD, PhD

Transforming the Drug Cost Paradigm from Payment for Medications to Payment for Value

William Fleming, PharmD

Healthcare Utilization and Costs of Knee or Hip Replacements versus Pain-Relief Injections

Margaret K. Pasqule, PhD, Anthony M. Louder, PhD, RPh, Raymond Y. Cheung, PhD, Andrew T. Reiners, MD, Robert J. Sanchez, PhD, Veerainder Goli, MD, MBA, DFAPA, Jack Mardekian, PhD

Stakeholder Perspective

Knee and Hip Pain: Rewarding Optimal Long-Term Management

by Steve Miff, PhD

Vyvanse (Lisdexamfetamine Dimesylate): First FDA-Approved Drug for the Treatment of Adults with Binge-Eating Disorder

Ibrance (Palbociclib): First CDK4 and CDK6 Inhibitor FDA Approved for the Treatment of Postmenopausal Women with Metastatic Breast Cancer

The Continuing Clinical and Economic Burden of Cardiometabolic Health

Dalia Buffery, MA, ABD

Compensation for Managing Population Health

David B. Nash, MD, MBA

Page 126 of 244
Results 1251 - 1260 of 2438